Editorial Board
Revision as of 19:58, 3 September 2019 by Warner-admin (talk | contribs)
Our editorial board is comprised of clinical and pharmacological experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
Peter C. Yang, MD Boston, MA Hem_Onc |
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
Jeremy L. Warner, MD, MS, FAMIA Vanderbilt University Nashville, TN Hemoncwarner |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
Associate Editors
Coming soon!
Section Editors
Breast Oncology | ||
---|---|---|
Hermina Fernandes, MD, FACP Bismarck, ND |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the Edith Sanford Breast Center at Sanford Health. She is a clinical assistant professor at the University of North Dakota. | |
Dermatologic Oncology | ||
Elizabeth Buchbinder, MD Boston, MA |
Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School. | |
Endocrine Oncology | ||
Jeena M. Varghese, MBBS Houston, TX |
Dr. Varghese is board certified in Internal Medicine and Endocrinology; she practices and is an assistant professor at the University of Texas MD Anderson Cancer Center. | |
Gastrointestinal Oncology | ||
Neeta K. Venepalli, MD, MBA Chicago, IL |
Dr. Venepalli is board certified in Medical Oncology; she practices at UI Health. She is an associate professor at the University of Illinois at Chicago. | |
Genitourinary Oncology | ||
Eddy J. Chen, MD Boston, MA |
Dr. Chen is board certified in Hematology and Medical Oncology; he practices at Massachusetts General Hospital. He is an instructor at Harvard Medical School. | |
Gynecologic Oncology | ||
Summer B. Dewdney, MD Chicago, IL |
Dr. Dewdney is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at Rush Copley Medical Center. She is an assistant professor at Rush University. | |
Head & Neck Cancer | ||
Michael Gibson, MD, PhD Nashville, TN mgibson21212 |
Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. | |
Neuro-Oncology | ||
Seema Nagpal, MD Palo Alto, CA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University | |
Sarcoma | ||
TBA | TBA | TBA |
Thoracic Oncology | ||
Travis Osterman, DO, MS Nashville, TN TravisOsterman |
Dr. Osterman is board certified in Medical Oncology and Clinical Informatics; he practices at Vanderbilt University Medical Center. He is an assistant professor at Vanderbilt University. | |
Acute Leukemias | ||
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO |
Dr. Schoen is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. | |
Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
Sanjay R. Mohan, MD, MSCI Nashville, TN |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. | |
Aggressive Lymphomas | ||
Jose C. Villasboas Bisneto, MD Rochester, MN |
Dr. Villasboas Bisneto is board certified in Hematology and Medical Oncology; he practices at the Mayo Clinic. | |
Indolent Lymphomas | ||
Sanjai Sharma, MD Visalia, CA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. | |
Plasma Cell Dyscrasias | ||
Andrew J. Cowan, MD Seattle, WA andrewcowanmd |
Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington. | |
T-cell and NK-cell neoplasms | ||
Unfilled | If you are interested, please feel free to contact us with any questions or inquiries, at [email protected]. | |
Lymphoproliferative disorders | ||
Unfilled | If you are interested, please feel free to contact us with any questions or inquiries, at [email protected]. | |
Histiocyte Disorders | ||
Ronald S. Go, MD Rochester, MN |
Dr. Go is board certified in Hematology and Medical Oncology; he practices at the Mayo Clinic, where he is an associate professor. | |
Immuno-Oncology | ||
Meghan J. Mooradian, MD Boston, MA |
Dr. Mooradian is board certified in Medical Oncology; she practices at Massachusetts General Hospital. She is an instructor at Harvard Medical School. | |
Pediatric Oncology | ||
Wayne H. Liang, MD, MS Birmingham, AL WayneLiangMD |
Dr. Liang is board certified in Pediatrics and Pediatric Hematology-Oncology; he practices at Children's of Alabama. He is an assistant professor at UAB. | |
Transplant | ||
Aric C. Hall, MD Madison, WI AricHall1 |
Dr. Hall is board certified in Hematology and Medical Oncology; he practices at UW Health. He is an assistant professor at the University of Wisconsin. | |
Classical Hematology | ||
Benjamin Tillman, MD Nashville, TN |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
COI Disclosures
To be completed; please see our conflict of interest page for more details.
Name | Research funding | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
---|---|---|---|
Dr. Liang | Nothing to disclose | Nothing to disclose | Sept. 17, 2018 |
Dr. Tillman | Nothing to disclose | Nothing to disclose | Sept. 13, 2018 |
Dr. Warner | NIH; Vanderbilt University | Travel: AACR; ASCO Ownership: HemOnc.org Consulting: Westat |
July 22, 2019 |
Dr. Villasboas Bisneto | DoD; Lymphoma Research Foundation | Nothing to disclose | Sept. 13, 2018 |
Dr. Yang | Nothing to disclose | HemOnc.org; stock: Merck, Pfizer | Oct. 3, 2018 |